# Cellectis S.A. American (CLLS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.24, market value $326 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cellectis S.A. American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 5.8×**. Each dollar of revenue is priced at 5.8×.
- **Price / book: 5.7×**. The shares trade at 5.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -13.8%** (5-yr avg -27.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 82.3%**. Cellectis S.A. American keeps 82.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -102.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -92.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -89.1%**. Return on equity is negative because earnings are negative.
- **Return on assets: -20.1%**. Each dollar of assets produces -20.1% of profit.

## Growth
- **Revenue growth (1 yr): 75.8%** (3-yr 56.1%/yr, 5-yr 7.4%/yr). Revenue grew 75.8% over the last year, against 7.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -63.4%**. Earnings per share fell 63.4%, slower than revenue, so margins compressed.

## Financial health
- **Interest coverage: -7.2×**. Operating profit covers interest only -7.2×: fragile.
- **Altman Z-score: 1.00**. A Z-score of 1.00 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Cellectis S.A. American does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 23.2%** (YTD -33.1%, 3-mo 5.9%). The shares are up 23.2% over twelve months including dividends.
- **From 52-week high: -40.9%** (37.9% above the low). Trading 41% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.75** (volatility 75%). Beta of 1.75 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CLLS · Page: https://foliofundamentals.com/stocks/clls

Not investment advice.